



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

August 9, 2023

Corporate Relationship Department  
M/s. BSE Ltd.  
Dalal Street, Fort  
**Mumbai 400 001**

Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) **Mumbai 400 051**

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Please find enclose herewith the disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for your information.

Thanking you,

Yours faithfully  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

**Ref: PR/05/2023-24**

**Press Release**

Hyderabad, 9<sup>th</sup> August, 2023

### **NATCO records ₹1160.2 Crore consolidated revenue and ₹420.3 Crore of profit, after tax, for the First Quarter, FY2023-24**

Hyderabad based NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has recorded consolidated total revenue of ₹1160.2 Crore for the first quarter ended on 30<sup>th</sup> June 2023, as against ₹918.9 Crore for the same period last year, reflecting a growth of 26.3%. The net profit for the period, on a consolidated basis, was ₹420.3 Crores as against ₹320.4 Crore same period last year, showing 31.2% growth.

The company had made a provision of ₹51.0 Crore towards pending patent infringement litigation cases for its products in India (without admission of either liability for infringement or validity of such patents) and also incurred about ₹17.0 Crore towards special incentive to employees.

Major drivers of business during the quarter were from formulation exports, strong growth in domestic business of both Pharma and Agro, and steady sales from subsidiaries.

Segmental Revenue Split (All Figures in ₹ Crore)-

Segment	Revenue, Q1 FY24	Revenue, Q4 FY23	Revenue, Q1 FY23
API	75.1	72.8	50.8
Formulations, Domestic	132.4	91.8	88.5
Formulations, Exports (incl. Profit Share & Foreign Subs)	884.2	709.2	736.9
Other Operating income & non-operating income	23.8	26.1	41.7
Crop Health Sciences (CHS)	44.7	27.0	1.0
<b>TOTAL</b>	<b>1160.2</b>	<b>926.9</b>	<b>918.9</b>

The Board of Directors has declared an interim dividend of ₹7/- (350%) per equity share of ₹2/- each, for the FY2024.

---

For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer